MiRNAs and Tempol Therapeutic Potential in Prostate Cancer: a Preclinical Approach

Overview

Journal J Mol Histol

Date 2025 Jan 13

PMID 39804465

Authors

Isabela Maria Urra Rossetto

Leticia F Alves

Leonardo A Marson

Murilo V Geraldo

Felipe R Santos

Fabio Montico

Valeria H A Cagnon

Affiliations

Soon will be listed here.

Abstract

This study investigated tempol action on genes and miRNAs related to NFκB pathway in androgen dependent or independent cell lines and in TRAMP model in the early and late-stages of cancer progression. A bioinformatic search was conducted to select the miRNAs to be measured based on the genes of interest from NFκB pathway. The miR-let-7c-5p, miR-26a-5p and miR-155-5p and five target genes (BCL2, BCL2L1, RELA, TNF, PTGS2) were chosen for RT-PCR and gene enrichment analyses. In vitro, PC-3 and LNCaP cells were exposed, respectively, to 1.0 or 2.0 mM of tempol during 48 h. In vivo, five experimental groups were evaluated regarding tempol effects in the early (CT12 and TPL12 groups) and late-stages (CT20, TPL20-I and TLP20-II) of PCa development. TPL groups were treated with 50 mg/kg or 100 mg/kg of tempol. The ventral lobe of the prostate and the plasma was collected. Tempol treatment increased miRs expression in PC-3 and LNCaP. For both cell lines, tempol decreased RELA expression. In TRAMP model, tempol increased miRNA expression in prostate for all treated groups. Tempol upregulated the miRNA expressions related to the NFκB pathway in the prostate tissue and human tumor cell lines. Their increase is mainly linked to increased cell death and delayed CaP aggressivenes. Thus, tempol's capacity for miRNA-mediated gene silencing to decrease tissue proliferation and cell survival processes is part of its tissue mechanics.

References

Chen J, Zhang K, Xu Y, Gao Y, Li C, Wang R . The role of microRNA-26a in human cancer progression and clinical application. Tumour Biol. 2016; 37(6):7095-108. DOI: 10.1007/s13277-016-5017-y. View

Chen Y, Zhou X, Wu Y . The miR-26a-5p/IL-6 axis alleviates sepsis-induced acute kidney injury by inhibiting renal inflammation. Ren Fail. 2022; 44(1):551-561. PMC: 9067948. DOI: 10.1080/0886022X.2022.2056486. View

Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View

Guo K, Zheng S, Xu Y, Xu A, Chen B, Wen Y . Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumour Biol. 2016; 37(9):12843-12854. DOI: 10.1007/s13277-016-5158-z. View

Hayden M, Ghosh S . Regulation of NF-κB by TNF family cytokines. Semin Immunol. 2014; 26(3):253-66. PMC: 4156877. DOI: 10.1016/j.smim.2014.05.004. View

Kalliolias G, Ivashkiv L . TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2015; 12(1):49-62. PMC: 4809675. DOI: 10.1038/nrrheum.2015.169. View

Khan S, Ayub H, Khan T, Wahid F . MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer. Biochimie. 2019; 167:12-24. DOI: 10.1016/j.biochi.2019.09.001. View

Li T, Zhang T, Gao H, Wang H, Yan H, Wan Z . Tempol modulates lncRNA-miRNA-mRNA ceRNA networks in ovaries of DHEA induced PCOS rats. J Steroid Biochem Mol Biol. 2022; 226:106175. DOI: 10.1016/j.jsbmb.2022.106175. View

Liu Z, Feng J, Shi L, Xu J, Zhang B, Chen L . Influences of miR-155/NF-κB signaling pathway on inflammatory factors in ARDS in neonatal pigs. Eur Rev Med Pharmacol Sci. 2019; 23(16):7042-7048. DOI: 10.26355/eurrev_201908_18746. View

10.

Lu Y, Liu M, Guo X, Wang P, Zeng F, Wang H . miR-26a-5p alleviates CFA-induced chronic inflammatory hyperalgesia through Wnt5a/CaMKII/NFAT signaling in mice. CNS Neurosci Ther. 2023; 29(5):1254-1271. PMC: 10068476. DOI: 10.1111/cns.14099. View

11.

Nadiminty N, Tummala R, Lou W, Zhu Y, Shi X, Zou J . MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. PMC: 3316551. DOI: 10.1371/journal.pone.0032832. View

12.

Ouyang Y, Gao P, Zhu B, Chen X, Lin F, Wang X . Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells. Mol Med Rep. 2014; 11(2):1435-41. DOI: 10.3892/mmr.2014.2782. View

13.

Rossetto I, Santos F, Kido L, Lamas C, Montico F, Cagnon V . Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation. Prostate. 2022; 83(5):403-415. DOI: 10.1002/pros.24473. View

14.

Schroder S, Asimakopoulou A, Tillmann S, Koschmieder S, Weiskirchen R . TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells. Cytokine. 2020; 135:155214. DOI: 10.1016/j.cyto.2020.155214. View

15.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

16.

Stark T, Livas L, Kyprianou N . Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol. 2016; 4(4):455-63. PMC: 4708587. DOI: 10.3978/j.issn.2223-4683.2015.04.12. View

17.

Thomas R, Sharifi N . SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol Cancer Ther. 2011; 11(1):87-97. PMC: 3256291. DOI: 10.1158/1535-7163.MCT-11-0540. View

18.

Urabe F, Yamamoto Y, Kimura T . miRNAs in prostate cancer: Intercellular and extracellular communications. Int J Urol. 2022; 29(12):1429-1438. DOI: 10.1111/iju.15043. View

19.

Wilcox C . Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 2010; 126(2):119-45. PMC: 2854323. DOI: 10.1016/j.pharmthera.2010.01.003. View

20.

Yao L, Ma J, Zeng X, Ou-Yang J . MicroRNA-155-5p inhibits the invasion and migration of prostate cancer cells by targeting SPOCK1. Oncol Lett. 2020; 20(6):353. PMC: 7586282. DOI: 10.3892/ol.2020.12215. View